Most people who eat intuitively on semaglutide undereat significantly
The reason for this is two-fold, but it helps to understand a little bit about glucose metabolism for it all to make sense
The reasons for the change include high and sometimes unpredictable costs, troublesome side effects, and co-occurring health challenges
But now, as the FDA officially lifts that shortage, the foundation of this business model is crumbling, exposing a series of legal, ethical, and operational challenges that may have been overlooked from the start by those who dont live and breathe drug development
For the right person someone medically appropriate for semaglutide who is also low in B12 the combination can be a sensible, convenient way to address both at once
Clinical Trials and Efficacy In clinical trials, patients taking 7.2 mg of Wegovy lost 20.7% of their body weight compared to 17.5% with the current 2.4 mg dose over 72 weeks